Lucid Diagnostics (NASDAQ:LUCD) & LeMaitre Vascular (NASDAQ:LMAT) Critical Survey

Lucid Diagnostics (NASDAQ:LUCD) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for Lucid Diagnostics and LeMaitre Vascular, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	0	0	2	0	3.00
LeMaitre Vascular	0	2	5	0	2.71

Lucid Diagnostics currently has a consensus price target of $2.75, suggesting a potential upside of 195.79%. LeMaitre Vascular has a consensus price target of $73.83, suggesting a potential downside of 2.85%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than LeMaitre Vascular.

Profitability

This table compares Lucid Diagnostics and LeMaitre Vascular’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-2,169.07%	-901.79%	-121.11%
LeMaitre Vascular	16.99%	11.57%	10.02%

Institutional & Insider Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 10.8% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Lucid Diagnostics and LeMaitre Vascular’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$2.43 million	19.05	-$52.67 million	($1.27)	-0.73
LeMaitre Vascular	$199.89 million	8.53	$30.10 million	$1.51	50.33

LeMaitre Vascular has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Lucid Diagnostics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Summary

LeMaitre Vascular beats Lucid Diagnostics on 10 of the 14 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.